8-K current report · filed Oct 28, 2026

PALVELLA THERAPEUTICS, INC. (PVLA) 8-K Current Report: October 28, 2026

Item 8.01Item EX-99.1PVLA overview

Short answer

PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA filing acceptance for QTORIN 3.9% rapamycin gel, advancing the treatment toward potential U.S. approval.

PALVELLA THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA filing acceptance for QTORIN 3.9% rapamycin gel, advancing the treatment toward potential U.S. approval
  • Priority Review signals FDA consideration of an accelerated review timeline
  • PDUFA target action date: February 28, 2027
  • Potential regulatory catalyst for Palvella’s microcystic lymphatic malformation program and valuationிழமை

Item EX-99.1 · Exhibit EX-99.1

  • FDA accepted QTORIN rapamycin’s NDA and granted Priority Review, establishing a February 28, 2027 PDUFA target date
  • Potential first FDA-approved therapy for microcystic lymphatic malformations, addressing more than 30,000 diagnosed U.S. patients
  • Phase 3 SELVA met all six prespecified efficacy endpoints with p<0.001; 95% improved on the primary mLM-IGA endpoint
  • No drug-related serious adverse events reported; systemic rapamycin concentrations remained below 2 ng/mL
  • Standalone U.S. launch targeted for first half of 2027, contingent on approval, marking potential transition to commercial-stage operations

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PALVELLA THERAPEUTICS, INC. 8-K filings

Get the next PVLA 8-K as it lands

Follow PVLA for push alerts, or ask the research agent what this filing means.